[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"veno-occlusive-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:veno-occlusive-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100515101","phase-2-defibrotide-dose-escalation-for-sos-post-hsct-100515101",false,"NCT05987124","Defibrotide Dose-escalation for SOS Post-HSCT","A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients With Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated With Either Renal and\u002For Pulmonary Dysfunction With Either Refractory or Progressive Disease Following Defibrotide Therapy","Inclusion Criteria:\n\n* HCT recipients (Auto or Allograft)\n* SOS\u002FVOD as defined by Cairo\u002FCooke Diagnostic criteria (1) (Table 3) with either renal and\u002For pulmonary dysfunction as defined by Cairo\u002FCooke Grading criteria (1) (Appendix I).\n* Unresponsive to standard defibrotide therapy as defined by at least one of the following:\n* Patients with SOS\u002FVOD failing to obtain a complete response (CR) defined by Grade I or less by Cairo\u002FCooke Grading criteria (1) (Appendix I). This would therefore include patients with stable disease after at least 14 days of defibrotide or partial response after at least 21 days of defibrotide (25mg\u002Fkg\u002Fday).\n* Progressive disease defined by progression of at least one grade or more from diagnostic grade as defined by Cairo\u002FCooke Grading criteria (1) (Appendix I) following at least 7 days of defibrotide (25mg\u002Fkg\u002Fday).\n* Age 1 month - 75 years\n\nExclusion Criteria:\n\n* Patients who did not receive HCT.\n* Concomitant systemic anticoagulation (excluding central venous line management, fibrinolytic instillation for central venous line occlusion, management of intermittent dialysis or ultrafiltration of CVVH).\n* Active bleeding and\u002For hemorrhage of at least grade 2 and above.\n* History of development of Grade III\u002FIV anaphylaxis probably or directly secondary to defibrotide.\n* Female patients who are pregnant or breast feeding.","ALL","1 Month","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)\u002Fveno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and\u002For lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.",[27,28],"Sinusoidal Obstruction Syndrome","Veno-occlusive Disease","RECRUITING","2026-04-10",{"date":32,"type":33},"2026-04-15","ACTUAL",{"date":35,"type":33},"2024-03-20",{"date":37,"type":21},"2028-08-01",{"name":39,"class":40},"New York Medical College","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100560634","phase-4-ketorolac-for-acute-vaso-occlusive-crisis-in-pediatric-sickle-cell-disease-100560634","NCT06579703","Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease","Ketorolac Dosing for Acute Vaso-Occlusive Crisis in Pediatric Patients With Sickle Cell Disease","Inclusion Criteria:\n\n* Pediatric patients with sickle cell disease (any genotype) who present to DCMC Emergency department or outpatient hematology clinic with acute pain.\n\nExclusion Criteria:\n\n* Patients receiving NSAID medication \\\u003C6 hours from presentation\n* known kidney injury\n* sickle nephropathy\n* bleeding concerns\n* allergy to NSAID medication\n* chronic pain patient\n* hemodynamic instability as defined by the treating provider","1 Day","21 Years",{"count":52,"type":21},102,[54],"PHASE4","Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg\u002Fkg\u002Fdose IV (\\\u003C16yo max 15mg, \\>16yo max 30mg) x 1 dose.",[57,58,28],"Sickle Cell Disease","Sickle Cell Crisis","NOT_YET_RECRUITING","2024-08-28",{"date":62,"type":33},"2024-08-30",{"date":64,"type":21},"2024-09-30",{"date":66,"type":21},"2028-02-15",{"name":68,"class":40},"Children's Blood and Cancer Center at Dell Children's Medical Center"]